Get the app!
Back to Trades
Total Value
$636.9K
Filing Date
Jun 18, 2026
1 transactions

Trade Summary

On Jun 17, 2026, RA CAPITAL MANAGEMENT, L.P., Insider, reported $636.9K of Sionna Therapeutics, Inc. (SION) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Reported prices ranged from $36.73. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Company Information

Ticker Symbol
SION
CIK
0002036042

Insider Information

Role
Insider
Location
BOSTON, MA

Filing Details

Filing Date
Jun 18, 2026
Transaction Date
Jun 17, 2026
Accession Number
0001231919-26-000674
Form Type
4

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Jun 17, 2026SION derivative17,340$36.73Grant/Award$636.9K

Want live alerts when RA CAPITAL MANAGEMENT, L.P. trades again?

Download Insider Trades to track SION, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

Footnotes

  1. (F1)The shares underlying the option vest in full upon the earlier of June 17, 2027 or the date of the Issuer's next annual meeting, subject to Dr. Resnick's continued service through such date.
  2. (F2)RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his pecuniary interest therein.
  3. (F3)Under Dr. Resnick's arrangement with the Adviser, Dr. Resnick holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund III, and the Account. Dr. Resnick is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the stock option and underlying Common Stock.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.